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For decades, the traditional pharmacological management of osteoarthritis
(OA) has been mainly symptomatic, despite a lack of evidence of its
influence on the duration of the disease and its progression. However, in
recent years several sets of guidelines, recommendations or points to
consider have been issued by regulatory authorities or scientific groups
regarding requirements for the registration of drugs to be used in the
treatment of OA. The ideal outcomes currently include pain and function
assessment for symptom-modifying drugs, and joint-space narrowing (JSN)
assessed by plain radiography for structure-modifying compounds. Taking
advantage of these more precise recommendations, several chemical
entities have been carefully investigated for the management of OA. 
This article provides a summary of the available evidence
demonstrating that some compounds can effectively interfere with the
structural progression of the disease. 
Avocado/Soybean Unsaponifiables
The unsaponifiable part of avocado (A) and soybean (S) oils (ASU)
mixed in a ratio of 1:2 (A1:S2) has been investigated in the treatment
of connective tissues, including in OA, for several years. A pilot
randomised, double-blind, placebo-controlled trial with follow-up over
two years failed to demonstrate a structural effect of ASU in 163
patients with painful hip OA.1 However, in a post hoc analysis a
significant difference was detected in the subgroup with a baseline
joint-space width (JSW) smaller than 2.45mm: joint space loss was
halved in the treated group (-0.43±0.51mm) compared with the
placebo group (-0.86±0.62mm; p=0.01). This finding suggests that
ASU may have a structure-modifying effect in patients with severe 
hip OA.
Chondroitine Sulphate
Chondroitine sulphate (CS) is a major component of the extra-cellular
matrix from many connective tissues, including – but not limited to –
cartilage, bone, skin, ligaments and tendons. In the articular cartilage,
the high content of CS in the aggrecan plays a major role in creating
considerable osmotic swelling pressure, which expands the matrix and
places the collagen network under tension. In a pilot double-blind
study, JSW measurement on digitalised radiographs of the extended
knees was used to compare the effects of CS 800mg/day and a
placebo in patients with knee OA.2 There were 23 patients in each
group. After one year, JSW was unchanged in the treated group but
had decreased by 0.4mm in the placebo group (p<0.005). No
significant difference was found for JSW at the narrowest site. The
small number of patients for whom end-point values were available
(12 in the placebo group and 14 in the CS group) limits the relevance
of the results. 
Another study randomised a total of 120 patients with symptomatic
knee OA into two groups receiving either 800mg CS or placebo per
day for two periods of three months during one year.3 Radiological
progression was assessed as a secondary outcome by automatic
measurement of medial femoro-tibial JSW on weight-bearing X-rays of
both knees. Radiological progression at month 12 showed significantly
decreased JSW in the placebo group, with no change in the CS group. 
More recently, a randomised, double-blind, placebo-controlled trial
randomly assigned 300 patients with knee OA to receive either CS
800mg or placebo once daily for two years.4 The primary outcome was
joint-space loss over two years as assessed by a postero-anterior
radiograph of the knee in flexion. The 150 patients receiving placebo
had progressive JSN, with a mean standard deviation (SD) joint-space
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loss of 0.14±0.61mm after two years (p=0.001 compared with
baseline). In contrast, there was no change in mean JSW for the 150
patients receiving CS (0.00±0.53mm; p = insignificant compared with
baseline). Similar results were found for minimum JSN. The differences
in loss of joint space between the two groups were significant for
mean JSW (0.14±0.57mm; p=0.04) and for minimum JSW
(0.12±0.52mm; p=0.05). 
Diacerein
In a randomised, double-blind, placebo-controlled three-year study,
507 patients with primary OA of the hip – according to American
College of Rheumatology (ACR) criteria – received diacerein 50mg or
placebo twice daily.5 The minimal hip JSW was measured by a central
reader on annual pelvic digitalised radiographs using a 0.1mm
graduated magnifying glass. No significant difference in the rate of
joint-space loss was found between the two groups in the intention-
to-treat analysis. In the study completers, however, joint-space loss
was significantly reduced in the diacerein group (-0.18±0.25mm)
compared with the placebo group (-0.23±0.23mm; p=0.042). In
addition, the percentage of patients with definite joint-space loss
(>0.5mm, which was the measurement error counted as two SDs of
the intra-observer reproducibility) was smaller in the diacerein group
than in the placebo group (50.7 versus 60.4%; p=0.036). Total hip
replacement of the signal hip during the study and during the three
months following discontinuation of the study treatment was
performed in 87 patients: 14.5% in the diacerein group and 19.8% in
the placebo group. The comparison of the two groups showed a trend
in favour of diacerein treatment that did not reach statistical
significance (p=0.29), but it should be emphasised that the study was
not powered for this outcome measure. 
Doxycycline
The structural effect of doxycycline was recently assessed in 431 obese
women aged 45–64 years with unilateral radiographic knee OA who
were randomly assigned to receive 30 months of treatment with
doxycycline 100mg or placebo twice daily.6 The co-primary end-points
were the evolution of JSN in the index knee (which exhibited
radiographic evidence of established OA at baseline) and in the
controlateral knee (in which radiographic evidence of tibiofemoral OA
was absent at baseline). After 16 months of treatment, the mean SD
loss of JSW in the index knee in the doxycycline group was 40% lower
than that in the placebo group (0.15±0.42 versus 0.24±0.54mm);
after 30 months, it was 33% lower (0.30±0.60 versus 0.45±0.70mm).
In contrast, doxycycline did not have an effect on JSN in the
contralateral knee; therefore, the two co-primary end-points were not
successfully met and this study should be considered a failure. The use
of a manual measurement of JSW instead of the most updated
automated technologies following X-ray digitalisation, as well as the
fact that the procedure was not blinded for measurement of JSW to
the sequence of the radiographs (i.e. baseline, month 16, month 30),
are potential methodological issues that deserve further debate.
Glucosamine Sulphate
Glucosamine is an aminosaccharide, acting as a preferred substrate for
the biosynthesis of glycosaminoglycan chains and, subsequently, 
for the production of aggrecan and other proteoglycans and cartilage.
To test the long-term effects of glucosamine sulphate (GS) on the
progression of OA knee joint structural changes and symptoms, 212
patients with knee OA were randomly assigned in a double-blind
fashion to continuous treatment with GS 1500mg or placebo once
daily for three years.7 Weight-bearing, anteroposterior radiographs of
each knee were taken at enrolment and every year for three years.
Total mean JSW of the medial compartment of the tibiofemoral joint
was assessed by digital image analysis based on a validated
computerised algorithm. After thee years, placebo-treated patients
had an average JSN of -0.31mm (range: -0.48 to -0.13), while no JSN
(-0.06mm, range: -0.22 to 0.09) occurred in the group treated with GS
(p=0.043). Furthermore, the percentage of patients who experienced
a clinically relevant (>0.5mm) mean JSN after three years was
significantly lower in the GS group (15%) than in the placebo group
(30%; p=0.013). 
A five-year follow-up evaluation of patients from this trial was
performed to assess long-term outcomes of disease progression after
the end of the study.8 The primary end-point of this follow-up study
was the occurrence of OA-related joint surgery. Of the 177 patients
participating in this follow-up evaluation, 26 (14.7%) underwent 
OA-related lower-limb surgery during the follow-up. Twice as many
patients from the former placebo group underwent surgery, with a
48% decrease in risk with GS that was borderline statistically
significant (p=0.06). The time-to-event analysis confirmed the results
of the crude primary outcome, indicating a decreased cumulative
incidence of OA-related lower limb surgeries for the patients formerly
on GS (p=0.05). When only total hip and/or knee replacements were
considered, the trend was similar, with over 40% reduction in risk
after GS, but the level of probability was lower and showed a trend
only towards the significance threshold (p<0.2). 
The structure-modifying effect of GS was later confirmed by a similar
trial in a population of 202 subjects from both sexes with a slightly
worse degree of knee OA.9 In this trial, the sparing effect of GS
1,500mg/day on the rate of progression of the disease was statistically
significant as early as the first year, and remained so until the end of
the three-year follow-up. The authors also described a significant
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reduction in the proportion of patients with a worse osteophyte 
score at the end-point (20% in the placebo versus 6% in the GS
group; p=0.03).
Intra-articular Hyaluronic Acid
Hyaluronate was evaluated in a one-year randomised controlled pilot
study in patients with knee OA evaluated by arthroscopy.10 Of the 
39 included patients, 36 were evaluated after one year. Hyaluronate
was injected into the joint once a week for three weeks, at intervals of
three months. Lesion severity was evaluated using the score developed
by the French Society for Arthroscopy. After one year, the score was
significantly lower in the treated group than in the control group
(p=0.05). However, no significant difference was found for JSW
measured on radiographs.
Hyaluronate has also been evaluated versus a placebo in 319 patients
with knee OA. JSW was measured on conventional extended-knee
radiographs. After one year, no significant difference was found
between the two treatment groups. However, in the subgroup of
patients whose JSW was >4.6mm at baseline, joint-space loss was
reduced in the hyaluronate group compared with the placebo 
group (p=0.02).11
Another study aimed to evaluate the long-term efficacy of three
iterative courses of three weekly intra-articular (IA) injections of the
hyaluronic acid (HA) compound NRD101 in the treatment of
symptomatic knee OA.12 In this placebo-controlled study of 301
patients aged over 50 years with painful and radiological medial knee
OA, patients were randomly assigned into three groups: group 1
received IA injections of HA and oral placebo; group 2 received IA
injections of saline solution and diacerein 100mg/day; and group 3
received IA injections of saline solution and oral placebo. After one
year of follow-up, JSW deteriorated (-0.09mm; n=277; p=0.01), but
with no difference between the groups (p=0.82). Percentages of
progressors (JSN >0.5mm) were 17.7, 18.9 and 20.3% (p=0.90) in
groups 1, 2 and 3, respectively.
Risedronate
The efficacy and safety of risedronate in patients with knee OA was
assessed in the British study of Risedronate In Structure and symptoms
of Knee OA (BRISK).13 BRISK was a one-year, prospective, double-blind,
placebo-controlled study. Patients were randomised to once-daily
risedronate 5 or 15mg or placebo. Radiographs were taken at baseline
and one year for assessment of JSW using a standardised radiographic
method with fluoroscopic positioning of the joint. Overall, the
difference between treatment groups in terms of loss of JSW at 12
months was not statistically significant (p=0.275). A post hoc analysis
of the distribution of change from baseline values in JSW at one year
showed a greater presence of detectable progression (i.e. loss of JSW
≥25% or ≥0.75mm) in the placebo (8%) and risedronate 5mg (4%;
p=0.36) groups than in the risedronate 15mg group (1%; p=0.067).
The results of a two-year multicentre international study of risedronate
in knee OA, presented in an international meeting,14 found no drug
effect at a dose of 5 or 15mg on JSW changes compared with placebo.
Conclusion
Several compounds have shown small to moderate structural efficacy
in OA. So far, the most compelling evidence of potential for inhibiting
the progression of OA is obtained with GS, while some research also
suggests that ASU, CS, diacerein or doxycycline could be used in the
same indication. The structure-modifying effects of other compounds
(i.e. alendronate, strontium ranelate, calcitonin, zoledronate and
selective oestrogen receptor modulator) are supported by pre-clinical
data and should be investigated for this specific purpose. It should be
borne in mind that all conclusive results were obtained with
prescription drugs containing these substances and should not be
extrapolated to over-the-counter or food supplements, whose content,
pharmacokinetics and pharmacodynamics are not guaranteed. ■
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